Back
United Therapeutics Corporation (UTHR)
BiotechnologyUTHR · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$518.62
+1.17%Weekly undervalued picks (like UTHR)
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$27.86
ROE
20.3%
Gross margin
86.6%
Debt/Equity
Revenue growth
-1.6%
P/B ratio
Beta
Forward P/E
United Therapeutics Corporation — company intelligence
Earnings surprises
Q2 2026$7.27 vs $6.97 est+4.3%
Q1 2026$5.82 vs $7.01 est-16.9%
Q4 2025$7.70 vs $7.33 est+5.1%
Q3 2025$7.16 vs $7.33 est-2.3%
Analyst consensus · 22 analysts
18 Buy4 Hold0 Sell
Updated Aug 19, 2026
Insider activity · 90 days
18 buys164 sellsnet -137,680 shares
MAHON PAUL ASell 760 · Aug 6, 2026
MAHON PAUL ASell 1,360 · Aug 6, 2026
MAHON PAUL ASell 1,795 · Aug 6, 2026
Recent SEC filings
4 — Insider transaction reportAug 14, 2026
4 — Insider transaction reportAug 13, 2026
4 — Insider transaction reportAug 12, 2026
Latest news
United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns — ChartMill · 5d ago
United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play — ChartMill · 1w ago
Why No. 2 IBD 50 Stock, Liquidia, Dropped Despite Its Sales Beat — Yahoo · 1w ago
United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript — Yahoo · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks (like UTHR)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.